Repatha (evolocumab) / Dr. Reddy’s, Amgen, Astellas - LARVOL DELTA

Cholesterol, Cognition, and Controversy: A Case of Mood Disturbance on Repatha. (PubMed, Cureus) - "She was later switched to bempedoic acid and remained asymptomatic. This clinical course suggests a potential link between intensive LDL reduction and mood disturbances. While psychiatric side effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are rarely reported, this case raises awareness and underscores the need for mental health outcomes integration into future PCSK9 investigations."

Journal • Cardiovascular • CNS Disorders • Dyslipidemia • Mood Disorders • Psychiatry

Characterisation of a clinical trial-like population of high cardiovascular risk patients prior to myocardial infarction or stroke in the real world: design and protocol for a multidatabase retrospective cohort study. (PubMed, BMJ Open) - "The benefits of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in these patients, are currently being studied in the phase 3 Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV) trial...Approvals of the study protocol were obtained from relevant local ethics and regulatory frameworks for each participating database. The results of the study will be submitted to peer-reviewed scientific publications and presented at scientific conferences."

Clinical protocol • Journal • Real-world evidence • Retrospective data • Cardiovascular • CNS Disorders • Coronary Artery Disease • Diabetes • Dyslipidemia • Heart Failure • Metabolic Disorders • Myocardial Infarction • Peripheral Arterial Disease • Vascular Neurology

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin. (PubMed, Front Pharmacol) - "The SUCRA rankings were atorvastatin > inclisiran > placebo > evolocumab for new diabetes incidence. The FAERS study and meta-analysis indicate that inclisiran may carry a lower risk of new-onset diabetes than atorvastatin, warranting further investigation into inclisiran's impact on glycemic control."

Journal • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

The use of monoclonal antibodies for the treatment of atherosclerosis: current status and prospects. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "Notably, anti-PCSK9 antibodies like alirocumab and evolocumab have demonstrated significant reductions in LDL-C levels and cardiovascular events in large-scale clinical trials. Overall, monoclonal antibody therapy represents a significant advancement in the management of atherosclerosis, with ongoing research aimed at optimizing efficacy, safety, and accessibility. Future directions include the development of novel mAbs and combination therapies to further improve cardiovascular outcomes in patients with atherosclerotic disease."

Journal • Review • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dermatology • Dyslipidemia • Heart Failure • Immunology • Inflammatory Arthritis • Metabolic Disorders • Oncology • Psoriasis • Rheumatoid Arthritis • Rheumatology • IL17A • IL1B • TNFA

Carotid plaques stabilization and regression with evolocumab (ESC-WCC 2025) - No abstract available

Late-breaking abstract • Cardiovascular

NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency (ESC-WCC 2025) - No abstract available

Cardiovascular

Oxidized phospholipids (OxPLs) dynamics following acute myocardial infarction (MI): effects of PCSK9 inhibition with evolocumab (ESC-WCC 2025) - No abstract available

Cardiovascular • Myocardial Infarction

PCSK9 inhibitor improved cardiac function after acute myocardial infarction in rats. (PubMed, Microvasc Res) - "The PCSK 9 inhibitor evolocumab improved cardiac function in AMI rats, and the mechanism may be related to the RIPK1/RIPK3/MLKL pathway."

IO biomarker • Journal • Preclinical • Cardiovascular • Dyslipidemia • Metabolic Disorders • Myocardial Infarction • Oncology • BAX • BCL2 • CASP3 • CD31 • IL17A • IL1B • MLKL • PCSK9 • PECAM1 • RIPK1

Early TNF-alpha levels suppression by upstream evolocumab use in patients with acute myocardial infarction undergoing percutaneous coronary intervention (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Myocardial Infarction • TNFA

Effect of early initiation of evolocumab on lipid profiles changes in patients with ACS Undergoing PCI (C-STAR) (ESC-WCC 2025) - No abstract available

Clinical • Acute Coronary Syndrome • Cardiovascular

HANYANG-PICK: Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study (clinicaltrials.gov) - P4 | N=352 | Not yet recruiting | Sponsor: Hanyang University Seoul Hospital

New P4 trial • Cardiovascular • Coronary Artery Disease

Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells. (PubMed, BMC Cardiovasc Disord) - "PCSK9i exhibits pleiotropic effects beyond lipid-lowering by modulating endothelial activation, inflammation, and monocyte adhesion in Lp(a)-stimulated HCAECs. These findings provide mechanistic insights into the potential atheroprotective properties of PCSK9i, highlighting their role in early atherogenesis prevention."

Biomarker • Journal • Atherosclerosis • Cardiovascular • Inflammation • ICAM1 • IL6 • NOS3 • PCSK9 • SELP

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipid Profile and Cardiovascular Events in High-Risk Diabetic Patients. (PubMed, Cureus) - "All participants received proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab 75 mg or evolocumab 140 mg subcutaneously every two weeks) in addition to standard care. Conclusion PCSK9 inhibitors significantly improve lipid parameters and reduce cardiovascular event rates in high-risk diabetic patients who are inadequately controlled with statins alone. These findings support their role as an effective and safe adjunctive therapy for secondary cardiovascular prevention in diabetes."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

A Case Series of Heterozygous Familial Hypercholesteremia With PCSK9 Inhibitor Failure (ENDO 2025) - "Evolocumab was switched to alirocumab which initially reduced her LDL-C to 2.65 mmol/L (102.5 mg/dL), but it later rose again. Ezetimibe 10mg daily was added and patient is awaiting approval for inclisiran.CASE 2: An 18-year-old woman with type 1 diabetes and celiac disease was seen in September 2012 for dyslipidemia...Pravastatin 40 mg was started but discontinued due to myalgias...Further research is needed to understand the underlying mechanisms and the likelihood of this occurring in other patients. These cases also highlight the need for ongoing vigilance in patients with high cholesterol and HeFH to ensure optimal cardiovascular protection."

Clinical • Cardiovascular • Celiac Disease • Diabetes • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Immunology • Metabolic Disorders • Musculoskeletal Pain • Pain • Type 1 Diabetes Mellitus

PCSK9-Targeting Drugs and Gender: Are There Any Differences? (PubMed, J Clin Med) - "This study aimed to assess sex-specific differences in response to and tolerance of PCSK9-targeted therapies-monoclonal antibodies (evolocumab, alirocumab) and small interfering RNA (inclisiran)-as well as LDL-C goal attainment according to current ESC guidelines. Although treatment prescription and tolerance were similar between sexes, women showed smaller LDL-C reductions at the first follow-up (51.7 ± 23.9% vs. 57.3 ± 24.9%, p = 0.044). PCSK9-targeted therapies were effective in both sexes at third follow-up, although women showed a tendency toward a delayed response and lower target attainment, indicating the potential need for more personalized management strategies."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders

Features of the management of patients during changing the drugs that affect proprotein convertase subtilisin/kexin type 9 (PCSK9) (PubMed, Kardiologiia) - "Alirocumab and evolocumab directly block circulating PCSK9 in the blood, which leads to an immediate decrease in the blood concentration of LDL-C clinically manifested already on the 1st day after injection...Alirocumab demonstrated the greatest reduction in LDL-C (-56.5% compared to baseline in the first clinical case and -53% in the second), while the inclisiran treatment resulted in 31.4% and 36.2% decreases in LDL-C from baseline, respectively...However, if a change in therapy is necessary for a number of independent reasons, it is important to monitor blood levels of LDL-C on a regular basis due to the different lipid-lowering efficacy of the drugs. These cases illustrate the importance of a balanced approach to changes in the therapy for dyslipidemia when the patient has achieved the goal and is tolerating the treatment well."

Journal • Dyslipidemia • Metabolic Disorders

Pharmacoeconomic Aspects of Using New-Generation Drugs of the PCSK-9 Inhibitor Class and Those Utilizing the Effect of Ribonucleic Acid Interference in the Treatment of Patients With Hypercholesterolemia. (PubMed, Kardiologiia) - "Two analytical models were developed that include the structure and number of patients receiving a combination therapy (high-dose statins + ezetimibe + alirocumab/evolocumab/inclisiran). The increase in the regional budget will be related only with the annual increase in the number of patients with hypercholesterolemia. The sensitivity analysis showed the robustness of the results to changes in the initial parameter values.Conclusion      The treatment of patients with dyslipidemia and high risk of cardiovascular events with alirocumab/evolocumab/inclisiran as part of the combination therapy is an economically justified strategy in the settings of the regional healthcare system."

HEOR • Journal • Cardiovascular • Dyslipidemia • Metabolic Disorders

Impact of GLP-1 Analogs vs. Lipid Lowering Agents on Risk for Acute Pancreatitis in Hypertriglyceridemia: A TriNetX Analysis (ENDO 2025) - "There were 21,106 patients receiving treatment with a GLP-1 analog (Cohort A) and 296,961 patients taking lipid lowering agents which we defined as atorvastatin, rosuvastatin, pravastatin, simvastatin, fenofibrate, ezetimibe, icosapent ethyl, evolocumab (Cohort B). Furthermore, it may reduce mortality for patients who have failed other modalities for weight loss, which is consistent with our findings. Ongoing research is essential to understand the long-term outcomes of GLP-1 analog therapy."

Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Obesity • Pancreatitis • Severe Hypertriglyceridemia

Breaking the Triglyceride Barrier: A Case of Severe Hypertriglyceridemia Management (ENDO 2025) - "Pharmacologic therapy included continuation of rosuvastatin 40 mg, fenofibrate 160 mg, and ezetimibe 10 mg. Patient was also started on Icosapent ethyl 2 g twice daily and Levothyroxine (LTX) was increased from 125 mcg to 150 mcg due to an elevated TSH level of 10.4 µIU/mL with a free T4 of 1.0 ng/dL...The patient was also prescribed evolocumab, but insurance restrictions required specialist approval...For symptomatic severe HTG cases, particularly with acute pancreatitis, IV insulin and therapeutic plasma exchange are key treatment options. Further research is needed to assess long-term outcomes and the role of emerging therapies in severe HTG management."

Clinical • Cardiovascular • Dyslipidemia • Endocrine Disorders • Hypertension • Hypertriglyceridemia • Obesity • Pancreatitis • Severe Hypertriglyceridemia

Evinacumab as an Effective Treatment Option for Refractory Hypertriglyceridemia (ENDO 2025) - "Despite using atorvastatin 80 mg daily, fenofibrate 162 mg daily, icosapent ethyl 2 g twice daily, and evolocumab 140 mg every 2 weeks, she continued to have hypertriglyceridemia. Evinacumab may be an effective alternative agent for the management of chronic hypertriglyceridemia based on the robust effects seen in our patient. Future research is needed to explore evinacumab's therapeutic targets beyond LDL-C to better modify risk factors for atherosclerosis, as well as CAV progression in heart transplant recipients."

Atherosclerosis • Cardiomyopathy • Cardiovascular • Diabetes • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • ANGPTL3 • APOB

Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication. (PubMed, JACC Case Rep) - "This case identifies PCSK9 gene duplication as a potential mechanism underlying nonresponse to PCSK9 inhibition and suggests that higher dosing of PCSK9 inhibitors may overcome nonresponse in some patients."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Gene Therapies • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders • PCSK9

A Call for Use of Lipid Fractionation Studies in Patients With Abnormal Standard Lipid Profiles. (PubMed, JCEM Case Rep) - "She was started on a triple cholesterol management regimen of ezetimibe, evolocumab, and bempedoic acid, which improved lipid fractionation values and symptoms. This case highlights the utility of using lipid fractionation studies in addition to traditional lipid panels to best treat patients with abnormal lipid panels on lipid-lowering therapy."

Journal • Asthma • Cardiovascular • Coronary Artery Disease • Dermatology • Diabetes • Dyslipidemia • Endocrine Disorders • Familial Hypercholesterolemia • Genetic Disorders • Hypoglycemia • Immunology • Metabolic Disorders • Myocardial Ischemia • Pain • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Vitiligo

Factors correlated with non-early achievement of target low-density lipoprotein cholesterol level using PCSK9 inhibitors. (PubMed, Heart Vessels) - "We enrolled consecutive patients with dyslipidemia who received evolocumab due to very-high-risk...A multivariable analysis showed that a history of ACS was negatively and LDL cholesterol level > 144 mg/dL positively correlated with non-EAC. In conclusion, we induced PSCK9 inhibitors more aggressively in ACS, and we should pay attention to the patients with higher baseline LDL-c levels during the follow-up."

Journal • Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Diabetes • Dyslipidemia • Metabolic Disorders • Nephrology • Renal Disease

A Modified Sampson-NIH Equation with Improved Accuracy for Estimating Low Levels of Low-Density Lipoprotein-Cholesterol. (PubMed, Clin Chem) - "The modified Sampson equation shows improved accuracy compared to other equations for low LDL-C. It more accurately identifies high-risk patients, who are not at their LDL-C goals and could benefit from more intensive lipid-lowering therapy."

Journal • Cardiovascular • Dyslipidemia

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "Both drugs exhibited comparable safety profiles. https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier CRD42024505327."

Journal • Retrospective data • Review • Cardiovascular • Myocardial Infarction